Innovation Seed Grant
The Innovation Seed Grant from FAST funds bold, early-stage research to advance scientific understanding and treatment options for Angelman syndrome.
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling
Funding Amounts: $10,000–$50,000 per award; one-year duration; one-time funding
Summary: Supports high-risk, early-stage research with transformative potential for Angelman syndrome understanding and treatment.
Key Information: No indirect costs allowed; applications accepted year-round.
Description
The Innovation Seed Grant, offered by the Foundation for Angelman Syndrome Therapeutics (FAST), is designed to catalyze pioneering research that could drive transformative advances in the understanding and treatment of Angelman syndrome. The grant specifically supports high-risk, high-reward projects at the proof-of-concept stage, encouraging bold new ideas that address significant gaps in disease knowledge or facilitate current therapeutic programs. Funding is intended to help researchers generate preliminary data, enabling future applications for larger-scale support. Areas of focus include novel treatment strategies, identification of therapeutic targets, and biomarker discovery.
